P2RX7
P2X purinoceptor 7
As of the edition of 20 October 2026, P2RX7 (P2X purinoceptor 7, UniProt Q99572) has 4 drugs tested at it and 3 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q99572
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 4
- Disease areas
- Bones, joints and muscles; Immune system; Skin and connective tissue; Mental health
- Registered trials of its drugs
- 20
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 2 |
| Stopped | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| JNJ-54175446 | Went quiet | Phase 1 | none listed |
| AZD9056 | Stopped | Phase 2 | none listed |
| CE-224535 | Went quiet | Phase 2 | none listed |
| Zanvipixant | Active | Phase 2 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Engaged | 1 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| AstraZeneca | Route A |
| Pfizer | Route A |
The other 1 company at P2RX7
In the product3 companies in all; 1 is not named here, and no score is.
See the 3 companies at P2RX7, ranked, with the facts behind eachRequest access. Nothing is shown until you do.